CFM
ADPT icon

Capricorn Fund Managers’s Adaptive Biotechnologies ADPT Stock Holding History

Capricorn Fund Managers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Sell
22,693
-1,269,080
-98% -$19.4M 0.04% 156
2026
Q1 		$17.9M Buy
+1,291,773
New +$20.6M 2.8% 8

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capricorn Fund Managers's ADPT Position: Q2 2026 in Review

Capricorn Fund Managers reduced its Adaptive Biotechnologies (ADPT) stake by 98% in Q2 2026, selling an estimated $19.4M and leaving 22,693 shares worth $487K. The position accounts for 0.04% of the portfolio, ranked #156.

Capricorn Fund Managers first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $17.9M in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Capricorn Fund Managers held 22,693 shares of Adaptive Biotechnologies worth $487K as of Q2 2026.
  • Capricorn Fund Managers sold 1,269,080 Adaptive Biotechnologies shares in Q2 2026, an estimated $19.4M.
  • Adaptive Biotechnologies made up 0.04% of Capricorn Fund Managers's portfolio in Q2 2026, its #156 holding.
  • Capricorn Fund Managers first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • Capricorn Fund Managers's Adaptive Biotechnologies position peaked at $17.9M in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Capricorn Fund Managers's 13F filing for Q2 2026, filed 24 Jul 2026.